ClinicalTrialsFinder
RecruitingPhase 1NCT07231029

A Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

An Open-label Pharmacokinetic Study of TS-172 in Patients With Hepatic Impairment

Sponsor

Taisho Pharmaceutical Co., Ltd.

Enrollment

24 participants

Start Date

Dec 23, 2025

Study Type

INTERVENTIONAL

Conditions

Patients With Mild or Moderate Hepatic Impairment

Summary

An open-label study to evaluate the effect of TS-172 administration on pharmacokinetics in patients with hepatic impairment

Eligibility

Min Age: 18 YearsMax Age: 75 Years

Inclusion Criteria3

  • Japanese male and female patients whose age is >=18 and <=75 years at the time of obtaining informed consent
  • Patients with chronic hepatic impairment
  • Japanese male and female patients whose age is >=18 and <=75 years at the time of obtaining informed consent

Exclusion Criteria3

  • Patients with medical history of liver resection or liver transplantation
  • Patients with grade II or higher hepatic encephalopathy
  • Subjects with current condition or medical history of diseases that are ineligible for participation in the study

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGTS-172

Single oral administration of TS-172 20mg

Locations(1)

Taisho Pharmaceutical Co., Ltd selected site

Tokyo, Japan

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07231029